| Revision as of 18:52, 25 December 2024 editJesswade88 (talk | contribs)Autopatrolled, Extended confirmed users, New page reviewers, Pending changes reviewers7,654 edits STARTED PAGETag: Visual edit | Revision as of 19:01, 25 December 2024 edit undoWiiformii (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers29,399 editsm Typo fixing, typo(s) fixed: Associate Director → associate directorTag: AWBNext edit → | ||
| Line 5: | Line 5: | ||
| }} | }} | ||
| '''Silvia Chiara Formenti''' is an Italian-American physician, oncologist and Chair of the Department of Radiation Oncology at Weill Cornell. She is |
'''Silvia Chiara Formenti''' is an Italian-American physician, oncologist and Chair of the Department of Radiation Oncology at Weill Cornell. She is associate director of the Meyer Cancer Center. She investigates the role of ionising radiation on the immune system. She was elected to the ] in 2024. | ||
| == Early life and education == | == Early life and education == | ||
| Line 11: | Line 11: | ||
| == Research and career == | == Research and career == | ||
| Formenti works in radiation biology. She has studied the role of ionising radiation on the immune system, and shown how tumours respond better to a combination of radiotherapy and immune therapy.<ref>{{Cite web |title=Silvia Chiara Formenti, M.D. {{!}} Patient Care |url=https://weillcornell.org/scformenti |access-date=2024-12-25 |website=weillcornell.org}}</ref> |
Formenti works in radiation biology. She has studied the role of ionising radiation on the immune system, and shown how tumours respond better to a combination of radiotherapy and immune therapy.<ref>{{Cite web |title=Silvia Chiara Formenti, M.D. {{!}} Patient Care |url=https://weillcornell.org/scformenti |access-date=2024-12-25 |website=weillcornell.org}}</ref> | ||
| She has designed clinical trials for various cancers (metastatic breast, lung and melanoma). She showed that in the presence of an immune checkpoint blockade (e.g. ]) an irradiated metastatic tumour can become an immunogenic hub, and behave similar to a vaccine. When immunised against the metastatic tumour, the host develops an immune response that can reject other tumours. She has shown that localised radiation and immune checkpoint blockades can help patients enter remission. Her research has shown that it is possible to convert "immunogenically cold" (i.e. non-responsive) tumour into an "immunogenically hot" (i.e. responsive) tumour.<ref>{{Cite web |title=Silvia Formenti |url=https://www.bcrf.org/researchers/silvia-formenti/ |access-date=2024-12-25 |website=Breast Cancer Research Foundation |language=en-US}}</ref> | She has designed clinical trials for various cancers (metastatic breast, lung and melanoma). She showed that in the presence of an immune checkpoint blockade (e.g. ]) an irradiated metastatic tumour can become an immunogenic hub, and behave similar to a vaccine. When immunised against the metastatic tumour, the host develops an immune response that can reject other tumours. She has shown that localised radiation and immune checkpoint blockades can help patients enter remission. Her research has shown that it is possible to convert "immunogenically cold" (i.e. non-responsive) tumour into an "immunogenically hot" (i.e. responsive) tumour.<ref>{{Cite web |title=Silvia Formenti |url=https://www.bcrf.org/researchers/silvia-formenti/ |access-date=2024-12-25 |website=Breast Cancer Research Foundation |language=en-US}}</ref> | ||
| Line 17: | Line 17: | ||
| Formenti showed that radiotherapy modifies how breast cancer cells process biomolecules, activating signalling pathways that are activated in other viruses. She has developed new strategies to reduce the risk of cardiovascular toxicity during breast cancer radiotherapy. Her strategy prevents radiation fields damaging the lungs or heart. | Formenti showed that radiotherapy modifies how breast cancer cells process biomolecules, activating signalling pathways that are activated in other viruses. She has developed new strategies to reduce the risk of cardiovascular toxicity during breast cancer radiotherapy. Her strategy prevents radiation fields damaging the lungs or heart. | ||
| Formenti joined ] in 2015.<ref name=":0" /> In 2024 Formenti was elected to the ].<ref>{{Cite web |title=Silvia Formenti, Massimo Loda elected to National Academy of Medicine {{!}} Cornell Chronicle |url=https://news.cornell.edu/stories/2024/10/silvia-formenti-massimo-loda-elected-national-academy-medicine |access-date=2024-12-25 |website=news.cornell.edu |language=en}}</ref> |
Formenti joined ] in 2015.<ref name=":0" /> In 2024 Formenti was elected to the ].<ref>{{Cite web |title=Silvia Formenti, Massimo Loda elected to National Academy of Medicine {{!}} Cornell Chronicle |url=https://news.cornell.edu/stories/2024/10/silvia-formenti-massimo-loda-elected-national-academy-medicine |access-date=2024-12-25 |website=news.cornell.edu |language=en}}</ref> | ||
| == Select publications == | == Select publications == | ||
| Line 26: | Line 26: | ||
| == References == | == References == | ||
| {{Reflist}} | |||
Revision as of 19:01, 25 December 2024
| Silvia C. Formenti | |
|---|---|
| Alma mater | University of Milan University of Southern California |
| Scientific career | |
| Institutions | Weill Cornell Medicine New York University |
Silvia Chiara Formenti is an Italian-American physician, oncologist and Chair of the Department of Radiation Oncology at Weill Cornell. She is associate director of the Meyer Cancer Center. She investigates the role of ionising radiation on the immune system. She was elected to the National Academy of Medicine in 2024.
Early life and education
Formenti is from Milan. She completed her medical training at the University of Milan. She moved to the University of Southern California for her specialty training, where she focused on cancer immunology.
Research and career
Formenti works in radiation biology. She has studied the role of ionising radiation on the immune system, and shown how tumours respond better to a combination of radiotherapy and immune therapy.
She has designed clinical trials for various cancers (metastatic breast, lung and melanoma). She showed that in the presence of an immune checkpoint blockade (e.g. CTLA-4) an irradiated metastatic tumour can become an immunogenic hub, and behave similar to a vaccine. When immunised against the metastatic tumour, the host develops an immune response that can reject other tumours. She has shown that localised radiation and immune checkpoint blockades can help patients enter remission. Her research has shown that it is possible to convert "immunogenically cold" (i.e. non-responsive) tumour into an "immunogenically hot" (i.e. responsive) tumour.
Formenti showed that radiotherapy modifies how breast cancer cells process biomolecules, activating signalling pathways that are activated in other viruses. She has developed new strategies to reduce the risk of cardiovascular toxicity during breast cancer radiotherapy. Her strategy prevents radiation fields damaging the lungs or heart.
Formenti joined Weill Cornell Medicine in 2015. In 2024 Formenti was elected to the National Academy of Medicine.
Select publications
- Marie Vétizou; Jonathan M Pitt; Romain Daillère; et al. (5 November 2015). "Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota". Science. 350 (6264): 1079–1084. doi:10.1126/SCIENCE.AAD1329. ISSN 0036-8075. PMC 4721659. PMID 26541610. Wikidata Q35833921.
- M Zahidunnabi Dewan; Ashley E Galloway; Noriko Kawashima; J Keith Dewyngaert; James S Babb; Silvia C Formenti; Sandra Demaria (25 August 2009). "Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody". Clinical Cancer Research. 15 (17): 5379–5388. doi:10.1158/1078-0432.CCR-09-0265. ISSN 1078-0432. PMC 2746048. PMID 19706802. Wikidata Q37351567.
- Claire Vanpouille-Box; Amandine Alard; Molykutty J Aryankalayil; et al. (9 June 2017). "DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity". Nature Communications. 8: 15618. Bibcode:2017NatCo...815618V. doi:10.1038/NCOMMS15618. ISSN 2041-1723. PMC 5472757. PMID 28598415. Wikidata Q33804663.
References
- "Formenti, Silvia Chiara". vivo.weill.cornell.edu. Retrieved 2024-12-25.
- ^ "Silvia C. Formenti, MD". ICEC. Retrieved 2024-12-25.
- "Silvia Chiara Formenti, M.D. | Patient Care". weillcornell.org. Retrieved 2024-12-25.
- "Silvia Formenti". Breast Cancer Research Foundation. Retrieved 2024-12-25.
- "Silvia Formenti, Massimo Loda elected to National Academy of Medicine | Cornell Chronicle". news.cornell.edu. Retrieved 2024-12-25.